BioCentury | May 1, 2020
Distillery Therapeutics

Apoptosis metabolites for treating arthritis, lung graft rejection

DISEASE CATEGORY: Autoimmune disease; transplant INDICATION: Arthritis; graft rejection Two cocktails of metabolites released through PANX1, a membrane channel activated during apoptosis, could treat inflammatory arthritis and lung graft rejection. The cocktails are either a...
BC Extra | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
BC Extra | May 10, 2019
Clinical News

Polyphor valuation cut in half on halted Phase IIIs of antibiotic murepavadin

Polyphor lost CHF12.27 (48%) to CHF13.38 on Friday after announcing late Thursday that it suspended enrollment in a pair of Phase III trials of pneumonia antibiotic murepavadin (POL7080) after observing a higher-than-expected incidence of acute...
BC Extra | May 9, 2019
Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy  Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
BC Week In Review | Sep 7, 2018
Financial News

Novo's REPAIR fund makes first investment in Swiss antibiotic company

Novo Holdings A/S invested CHF6.8 million ($7 million) on Sept. 6 into antibiotic company Polyphor Ltd. (SIX:POLN) through the purchase of 178,947 new shares at CHF38. The funds come from Novo's REPAIR Impact Fund, which...
BC Week In Review | May 18, 2018
Financial News

Polyphor raises $155.3M Swiss IPO

Polyphor Ltd. (SIX:POLN) gained CHF0.20 to CHF38.20 in its first day of trading on May 15 after raising CHF155 million ($155.3 million) through the sale of 4.1 million shares at CHF38 in an IPO on...
BC Extra | May 15, 2018
Financial News

Polyphor ticks up after Swiss IPO

Polyphor Ltd. (SIX:POLN) gained CHF0.20 to CHF38.20 in its first day of trading Tuesday after raising CHF155 million ($155.3 million) through the sale of 4.1 million shares at CHF38 in an IPO on the SIX...
BC Week In Review | May 5, 2017
Clinical News

Polyphor reports Ph II murepavadin data

Polyphor Ltd. (Allschwil, Switzerland) reported that thrice-daily 2.5 mg/kg IV murepavadin (POL7080, RG7929) for 10-14 days plus standard of care (SOC) led to a clinical cure rate at the test-of-cure (TOC) visit 5-9 days after...
BC Extra | Apr 12, 2017
Financial News

Polyphor raises CHF40M in private placement

Antibiotic company Polyphor Ltd. (Allschwil, Switzerland) said it received CHF10 million ($9.9 million) of a tranched CHF40 million ($39.6 million) private placement. It is eligible to receive the balance next half, following an end-of-Phase II...
BC Innovations | Oct 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies identified a dual PDE-5 / HDAC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of molecules that combined structural features of known...
Items per page:
1 - 10 of 50